RevMAB

RevMAB is a private, revenue-generating biotech company with a focus on recombinant monoclonal antibody discovery and development. Its core technology enables the generation of rabbit and goat monoclonal antibodies for challenging targets, including specific mutations, post-translational modifications, and small molecules, which are difficult to address with conventional methods. The company operates a hybrid business model, offering custom antibody discovery services while also commercializing a catalog of research-use-only antibodies and raw materials for diagnostic assays. Its primary market opportunities lie in providing critical reagents for oncology diagnostics, companion diagnostics, and early-stage therapeutic antibody discovery.

Proprietary hybridoma-free method for generating recombinant monoclonal antibodies directly from antigen-specific B cells (rabbit and goat). Enables development of antibodies against difficult targets like mutations, small molecules, and complex epitomes with high specificity and consistency.

Operates in a crowded field dominated by giants like Abcam, Thermo Fisher, and Bio-Techne. Competes on technological differentiation (recombinant, hybridoma-free platform) and specialization in high-specificity, difficult-to-make antibodies for oncology and diagnostics. Also competes with other specialty antibody developers and CROs offering custom discovery services.